Bristol Myers Squibb to Present New Multiple Myeloma and Lymphoma Data at ASH 2026

Bristol Myers Squibb to Present New Multiple Myeloma and Lymphoma Data at ASH 2026

Bristol Myers Squibb has announced an extensive hematology research program for the 68th American Society of Hematology (ASH) Annual Meeting, scheduled for December 12–15, 2026, in New Orleans, Louisiana. The company and its research partners will contribute more than 90 scientific disclosures, including 24 oral presentations, covering multiple myeloma, lymphoma and rare hematologic disorders. Announced on November 19, the program includes Phase 3 data for iberdomide and mezigdomide, five-year follow-up of lisocabtagene maraleucel and early clinical findings from next-generation CAR T-cell therapies.

The presentations will examine several important questions in hematology: Can new oral combinations provide more durable disease control in multiple myeloma? Can cellular therapies achieve sustained remissions in aggressive lymphomas? And could targeting more than one antigen improve the effectiveness of CAR T-cell therapies in heavily pretreated patients?

Phase 3 Multiple Myeloma Data Take Center Stage

Among the most closely watched presentations will be updated findings from the Phase 3 EXCALIBER-RRMM trial, evaluating iberdomide in combination with daratumumab and dexamethasone against daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Iberdomide is a cereblon E3 ligase modulator (CELMoD), a class of therapies designed to promote targeted protein degradation and influence immune responses.

Bristol Myers Squibb previously reported that the iberdomide combination significantly improved progression-free survival in EXCALIBER-RRMM.

The results announced in October 2026 included:

  • Median progression-free survival: 42 months with iberdomide, daratumumab and dexamethasone versus 20 months in the comparator arm.
  • Hazard ratio: 0.49, representing a 51% relative reduction in the risk of progression or death.
  • Statistical significance: p<0.000001.
  • Median follow-up: 23 months.

Earlier trial results also demonstrated higher rates of minimal residual disease (MRD)-negative complete response with iberdomide, at 41.1% versus 20.7% (p<0.0001).

These MRD findings supported the FDA’s accelerated approval of iberdomide in August 2026 for eligible adults with previously treated multiple myeloma.

Bristol Myers Squibb to Present New Multiple Myeloma and Lymphoma Data at ASH 2026

At ASH 2026, investigators will provide further analyses of progression-free survival, sustained MRD negativity and safety. The updated findings are particularly relevant to understanding whether deeper responses translate into longer-term disease control.

Another important presentation will come from SUCCESSOR-2, the Phase 3 trial investigating mezigdomide, carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone.

Previously reported results showed median progression-free survival of 18 months versus 8.3 months, respectively. The ASH update will examine outcomes according to previous exposure to pomalidomide or T-cell-redirecting therapies, potentially providing additional evidence for treatment sequencing in patients with relapsed or refractory disease.

Next Generation CAR T Therapies Target Two Antigens

Beyond oral therapies, Bristol Myers Squibb will present early clinical results from a new generation of cellular immunotherapies.

One highlighted program is tunlucabtagene autoleucel (BMS-986453), an investigational autologous CAR T-cell therapy designed to target both BCMA and GPRC5D.

These proteins are expressed on multiple myeloma cells and are established targets for immunotherapeutic development.

By targeting two antigens, researchers aim to investigate whether this approach can address some mechanisms of treatment resistance associated with single-target cellular therapies.

The first-in-human Phase 1 study will report safety and efficacy findings in patients with relapsed or refractory multiple myeloma. The presentation is scheduled for December 12.

Another investigational CAR T-cell therapy, arlocabtagene autoleucel, targets GPRC5D alone. Its Phase 1 presentation will explore GPRC5D expression and genetic locus integrity in treated patients, providing information relevant to understanding antigen-related resistance.

Together, these programs represent different approaches to improving outcomes after multiple lines of therapy, although their long-term efficacy and safety require further evaluation.

Five-Year TRANSFORM Follow-Up Examines Long-Term CAR T Outcomes

In lymphoma, one of the notable presentations will be a five-year follow-up from the pivotal Phase 3 TRANSFORM trial, evaluating lisocabtagene maraleucel against standard-of-care treatment in patients with relapsed or refractory large B-cell lymphoma receiving second-line therapy.

Lisocabtagene maraleucel is a CD19-directed autologous CAR T-cell therapy already approved for several B-cell malignancy indications.

While earlier analyses established its clinical benefit, extended follow-up is important for determining the durability of remission, long-term survival and late treatment-related complications.

The five-year results will provide additional evidence regarding the potential for sustained disease control after CAR T-cell therapy, an important consideration when evaluating treatments given with curative intent.

Bristol Myers Squibb will also present a real-world analysis comparing the effectiveness and safety of lisocabtagene maraleucel with bispecific antibodies in second-line large B-cell lymphoma.

Golcadomide Explores a Chemotherapy-Free Approach in Follicular Lymphoma

Another area of interest is the development of golcadomide, an investigational oral CELMoD being evaluated in follicular lymphoma.

The Phase 2 GOLSEEK-2 study investigates golcadomide plus rituximab in patients with newly diagnosed, advanced-stage follicular lymphoma.

According to the published ASH abstract, the study enrolled 93 patients across two golcadomide dose groups and a rituximab-based chemotherapy group.

Among response-evaluable patients, the complete metabolic response rate was:

  • 79% with golcadomide 0.2 mg plus rituximab.
  • 100% with golcadomide 0.4 mg plus rituximab.
  • 94% with rituximab-based chemotherapy.

However, safety remains an important consideration. Grade 3 or higher neutropenia occurred in 54% and 85% of patients receiving golcadomide at 0.2 mg and 0.4 mg, respectively.

The study was designed for dose optimization and was not powered to establish superiority over chemotherapy-based treatment. Its findings therefore support further investigation rather than a definitive change in clinical practice.

Additional lymphoma presentations will explore golcadomide with obinutuzumab and in combination with polatuzumab-based immunochemotherapy, as well as the investigational BCL6 degrader BMS-986458.

Rare Hematologic Disorders Also Feature in the ASH Program

The research program extends beyond hematologic malignancies.

Bristol Myers Squibb will present Phase 2 results involving luspatercept in adults with non-transfusion-dependent alpha-thalassemia hemoglobin H disease and Phase 2a findings in adolescents with transfusion-dependent beta-thalassemia.

Additional presentations will examine luspatercept in myelodysplastic syndromes and myelofibrosis, including analyses of anemia management and clinical outcomes.

These studies address the ongoing need for improved treatment strategies in disorders characterized by chronic anemia and transfusion burden.

What the ASH 2026 Results Could Mean for Hematology

The Bristol Myers Squibb research program brings together several areas of hematology drug development, from oral protein degradation therapies to cellular immunotherapies and treatments for inherited blood disorders.

Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, emphasized the scope of the upcoming presentations, stating:

“At ASH, we’re highlighting the breadth of our work in blood cancers.”

The most clinically relevant questions will concern the durability of response, treatment safety, and the position of emerging therapies within increasingly complex treatment pathways.

For multiple myeloma, updated Phase 3 analyses may help clarify the clinical role of CELMoD-based combinations. In lymphoma, five-year CAR T-cell follow-up will contribute to the growing evidence on long-term outcomes. Meanwhile, early-stage dual-targeted cellular therapies will provide initial clinical evidence for strategies intended to address resistance.

The key distinction is that these studies are at different stages of development. Some investigate established treatments with mature follow-up, while others are first-in-human programs requiring larger and longer studies.

The full presentations at ASH 2026 will provide an opportunity to assess not only efficacy but also the safety and practical implications of these approaches for patients with blood cancers and hematologic disorders.

Read further on OncoDaily: 10 Key Trials to Watch at ASH 2026: Multiple Myeloma, Smoldering Myeloma, and AL Amyloidosis
Bristol Myers Squibb to Present New Multiple Myeloma and Lymphoma Data at ASH 2026

Nare Hovhannisyan
Fact checked by Nare Hovhannisyan MD, Medical Writer
Ani Minasaryan
Medically reviewed by Ani Minasaryan MD, KOL Intelligence Lead of BIGR, Editor at OncoDaily